A review found early self-reported benefits from ADHD medicines in perimenopause, but objective cognitive gains were unclear. Here's the clinical context.
On October 20, 2026, Psychiatric Times reported on a scoping review of lisdexamfetamine and atomoxetine for cognitive difficulties during perimenopause. The review was scheduled for presentation at The Menopause Society's 2026 Annual Meeting in San Diego.
The clinical boundary is between treating diagnosed ADHD and using ADHD medicines for concentration or memory changes around menopause. Those are different treatment questions. The Menopause Society's October 8 announcement said these medicines were not ready to be recommended for menopausal brain fog.
The new report tests that boundary rather than replacing it. Its relevance is the possibility of a future treatment role, not an announcement that routine prescribing should change. For readers, the distinction prevents research about a familiar symptom from being mistaken for an available answer.
According to Psychiatric Times, the review was titled Brain Fog or ADHD? Executive Dysfunction in Perimenopause: A Scoping Review of the Role of ADHD Medications. It examined original research rather than reporting a new clinical trial.
The Menopause Society's announcement also places forgetfulness and trouble concentrating among the cognitive changes reported during perimenopause. That context explains the interest in this work. It is separate from the medication result: recognising a symptom does not establish which treatment might be appropriate.
The positive signal concerns how participants rated their executive-function difficulties. That is a meaningful distinction for anyone trying to understand a headline about brain fog. A questionnaire result answers a question about reported experience; it should be described in those terms.
Self-reported improvement does not need to be dismissed simply because it is self-reported. In an editorial reading of these findings, women's descriptions deserve attention. The useful question is how closely the research outcome matches the claim being made about it.
For example, saying that participants reported fewer difficulties stays close to the result. Calling that result proof of better cognitive performance makes a much larger claim. The review supports interest in the first statement, not a shortcut to the second.
A brain-fog headline should also leave room for the woman behind the score. A concern about concentration may matter because it affects her daily experience, not only because it can be placed on a scale. Refemina's broader discussion of memory changes in midlife provides another place to keep that conversation in focus.
The Psychiatric Times account does not give the number of included studies or participants. It also omits effect sizes, confidence intervals and detailed study-level methods. Without those details, readers cannot judge the size or durability of any reported benefit or compare safety outcomes for this use.
The account describes supportive neuroimaging findings in a subset taking lisdexamfetamine. It does not supply the detail needed to assess that evidence independently. It also does not establish that participants in the medication studies had a formal ADHD diagnosis.
These gaps limit how far this conference-related coverage can take a clinical decision. The Menopause Society says larger studies are needed to confirm safety and effectiveness. That call is about resolving questions about benefit and risk, not simply repeating a positive headline.
Lead author Jennifer Tat suggested that screening for ADHD symptoms could help women access appropriate care, according to The Menopause Society. This was a comment on a possible route to assessment, not a treatment guideline.
A useful conversation can start with what has changed and how it affects everyday life. Rather than arriving with a request based on the medicine names in a headline, a woman can describe her concentration or memory concerns and ask what needs assessment. The research supports asking whether ADHD symptoms or another explanation should be part of that discussion.
A description such as difficulty concentrating is a starting point rather than a diagnosis. The next part is its impact: whether the change is disrupting activities that matter to that woman. This keeps the conversation centred on function and quality of life instead of asking her to fit a label before she has been assessed.
That distinction matters when confidence is involved. Bringing a concern to a clinician does not require adopting ADHD or menopause as its explanation in advance. The aim is to make the difficulty clear enough to discuss while leaving the assessment open.
Screening also needs to stay in its proper place. The lead author's suggestion is not proof that a screening result identifies the cause of midlife cognitive changes. Nor do the associations in this review show that treating one set of symptoms will resolve the other.
Questions worth bringing to that discussion include what the review measured and whether its population resembles the person seeking care. Another is what evidence would be needed before a medicine had a role. Such questions keep attention on the evidence without requiring a woman to minimise her symptoms or turn uncertainty into a self-diagnosis.
Readers following research on brain changes during menopause can apply the same discipline here: separate the finding from the individual decision. A study can raise a useful question without supplying a prescription for the person reading it.
These findings are not a basis for independently starting, stopping or adjusting either medicine. For someone already receiving ADHD care, they are not a personal instruction to change treatment. Decisions about an individual's care belong with a qualified clinician who can assess that person's situation.
For now, this review is more likely to sharpen conversations about midlife cognitive symptoms than to change prescribing, with any future medication role dependent on stronger clinical evidence.
Judging whether early brain-fog research warrants a medical discussion is the decision Refemina supports through evidence-led editorial coverage. For women whose changing concentration has unsettled their sense of competence or identity, the publication connects hormonal transition with confidence and personal change while distinguishing established knowledge from claims that still need testing.
Follow Refemina for research-led insights on menopause, strength, metabolism, nutrition, skin, intimacy and confidence through midlife. New articles turn complex topics into clear, useful context.
Keep learning about the changes that shape energy, strength, confidence and wellbeing through midlife.
Explore Resources